Bin Xu1, Talia Fuchs2, Snjezana Dogan1, Iñigo Landa3, Nora Katabi1, James A Fagin3,4, R Michael Tuttle4, Eric Sherman4, Anthony J Gill2, Ronald Ghossein1. 1. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 2. Sydney NSW Australia and Cancer Diagnosis and Pathology Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, Australia. 3. Human Oncology and Pathogenesis Program, and Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 4. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is nearly always fatal. Large studies on ATC are exceedingly rare. We aimed to study the clinical, genotypic, and histologic characteristics of ATC in the largest retrospective cohort of ATC to date. Methods: Three hundred sixty patients with ATC from two tertiary centers were studied. Molecular testing was performed in 126 cases including 107 using next-generation sequencing. Results: The median patients' age was 68 years. Differentiated thyroid carcinoma (DTC) was present in 208 cases (58%), the most common being papillary carcinoma (n = 150). The 1-, 2-, 3-, and 5-year overall survival (OS) was 36%, 17%, 13%, and 11%, respectively. On univariate analysis, age, resectability, chemotherapy, radiotherapy, margin status, encapsulation, gross residual disease, gross extrathyroidal extension, percentage, and size of ATC in the primary tumor predicted OS (p < 0.05). Age, resectability, chemotherapy, and gross residual disease were independent prognostic factors in the entire cohort, while gross residual disease was the only independent predictor of OS in patients who had resection of their tumor. BRAF, RAS, TERT promoter, TP53, PIK3CA, E1F1AX, and PTEN mutations were detected in 45%, 24%, 75%, 63%, 18%, 14%, and 14% of ATC, respectively. Concomitant BRAF/RAS and TERT mutations were associated with worse outcome than mutation in only one of the genes. BRAF-mutated and RAS-mutated ATCs had similar frequency of nodal and distant metastasis. Twelve cases were pure squamous cell carcinoma, 60% of which carried BRAFV600E mutation and showed a similar OS to other ATCs. Conclusions: (i) Gross residual disease remains the most crucial indicator of outcome in ATC. (ii) Encapsulation, margin status, percentage, and size of ATC in the primary were prognostically relevant. (iii) Pure thyroid squamous cell carcinoma may be considered as ATC given a BRAFV600E genotype and similar outcome. (iv) In contrast to DTC, BRAF-mutated and RAS-mutated ATCs have similar metastatic spread. (v) Concomitant mutations of BRAF or RAS with TERT confer a worse prognosis.
Background: Anaplastic thyroid carcinoma (ATC) is nearly always fatal. Large studies on ATC are exceedingly rare. We aimed to study the clinical, genotypic, and histologic characteristics of ATC in the largest retrospective cohort of ATC to date. Methods: Three hundred sixty patients with ATC from two tertiary centers were studied. Molecular testing was performed in 126 cases including 107 using next-generation sequencing. Results: The median patients' age was 68 years. Differentiated thyroid carcinoma (DTC) was present in 208 cases (58%), the most common being papillary carcinoma (n = 150). The 1-, 2-, 3-, and 5-year overall survival (OS) was 36%, 17%, 13%, and 11%, respectively. On univariate analysis, age, resectability, chemotherapy, radiotherapy, margin status, encapsulation, gross residual disease, gross extrathyroidal extension, percentage, and size of ATC in the primary tumor predicted OS (p < 0.05). Age, resectability, chemotherapy, and gross residual disease were independent prognostic factors in the entire cohort, while gross residual disease was the only independent predictor of OS in patients who had resection of their tumor. BRAF, RAS, TERT promoter, TP53, PIK3CA, E1F1AX, and PTEN mutations were detected in 45%, 24%, 75%, 63%, 18%, 14%, and 14% of ATC, respectively. Concomitant BRAF/RAS and TERT mutations were associated with worse outcome than mutation in only one of the genes. BRAF-mutated and RAS-mutated ATCs had similar frequency of nodal and distant metastasis. Twelve cases were pure squamous cell carcinoma, 60% of which carried BRAFV600E mutation and showed a similar OS to other ATCs. Conclusions: (i) Gross residual disease remains the most crucial indicator of outcome in ATC. (ii) Encapsulation, margin status, percentage, and size of ATC in the primary were prognostically relevant. (iii) Pure thyroid squamous cell carcinoma may be considered as ATC given a BRAFV600E genotype and similar outcome. (iv) In contrast to DTC, BRAF-mutated and RAS-mutated ATCs have similar metastatic spread. (v) Concomitant mutations of BRAF or RAS with TERT confer a worse prognosis.
Authors: Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin Journal: J Clin Invest Date: 2016-02-15 Impact factor: 14.808
Authors: Scott M Glaser; Steven F Mandish; Beant S Gill; Goundappa K Balasubramani; David A Clump; Sushil Beriwal Journal: Head Neck Date: 2016-02-19 Impact factor: 3.147
Authors: Bryan R Haugen; Daniel W Bowles; Nikita Pozdeyev; Laurie M Gay; Ethan S Sokol; Ryan Hartmaier; Kelsi E Deaver; Stephanie Davis; Jena D French; Pierre Vanden Borre; Daniel V LaBarbera; Aik-Choon Tan; Rebecca E Schweppe; Lauren Fishbein; Jeffrey S Ross Journal: Clin Cancer Res Date: 2018-04-03 Impact factor: 12.531
Authors: Michelle D Williams; Hui Chen; Rajyalakshmi Luthra; Mark J Routbort; Keyur P Patel; Maria E Cabanillas; Russell R Broaddus Journal: Mol Cancer Ther Date: 2018-04-25 Impact factor: 6.261
Authors: Naiyarat Prasongsook; Aditi Kumar; Ashish V Chintakuntlawar; Robert L Foote; Jan Kasperbauer; Julian Molina; Yolanda Garces; Daniel Ma; Michelle A Neben Wittich; Joseph Rubin; Ronald Richardson; John Morris; Ian Hay; Vahab Fatourechi; Bryan McIver; Mabel Ryder; Geoffrey Thompson; Clive Grant; Melanie Richards; Thomas J Sebo; Michael Rivera; Vera Suman; Sarah M Jenkins; Robert C Smallridge; Keith C Bible Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: Luc G T Morris; Raghu Chandramohan; Lyndsay West; Ahmet Zehir; Debyani Chakravarty; David G Pfister; Richard J Wong; Nancy Y Lee; Eric J Sherman; Shrujal S Baxi; Ian Ganly; Bhuvanesh Singh; Jatin P Shah; Ashok R Shaha; Jay O Boyle; Snehal G Patel; Benjamin R Roman; Christopher A Barker; Sean M McBride; Timothy A Chan; Snjezana Dogan; David M Hyman; Michael F Berger; David B Solit; Nadeem Riaz; Alan L Ho Journal: JAMA Oncol Date: 2017-02-01 Impact factor: 31.777
Authors: Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete Journal: Endocr Pathol Date: 2022-03-14 Impact factor: 3.943
Authors: Tam N M Ngo; Trang T B Le; Thoa Le; Andrey Bychkov; Naoki Oishi; Chan Kwon Jung; Lewis Hassell; Kennichi Kakudo; Huy Gia Vuong Journal: Endocr Pathol Date: 2021-09-24 Impact factor: 3.943
Authors: Bin Xu; Julia David; Snjezana Dogan; Iñigo Landa; Nora Katabi; Maelle Saliba; Anjanie Khimraj; Eric J Sherman; Robert Michael Tuttle; Giovanni Tallini; Ian Ganly; James A Fagin; Ronald A Ghossein Journal: Histopathology Date: 2021-10-07 Impact factor: 7.778
Authors: Xhesika Shanja-Grabarz; Anouchka Coste; David Entenberg; Antonio Di Cristofano Journal: Endocr Relat Cancer Date: 2020-10 Impact factor: 5.678
Authors: Ronald Ghossein; Justine A Barletta; Martin Bullock; Sarah J Johnson; Kennichi Kakudo; Alfred K Lam; Mufaddal T Moonim; David N Poller; Giovanni Tallini; R Michael Tuttle; Bin Xu; Anthony J Gill Journal: Hum Pathol Date: 2020-09-10 Impact factor: 3.466
Authors: Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark Journal: Thyroid Date: 2021-03 Impact factor: 6.568
Authors: Caitlin E Egan; Dessislava Stefanova; Adnan Ahmed; Vijay J Raja; Jessica W Thiesmeyer; Kevin J Chen; Jacques A Greenberg; Taotao Zhang; Bing He; Brendan M Finnerty; Rasa Zarnegar; Moonsoo M Jin; Theresa Scognamiglio; Noah Dephoure; Thomas Fahey; Irene M Min Journal: Thyroid Date: 2021-07-05 Impact factor: 6.506